Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Idiopathic hypersomnia
- Focus Therapeutic Use
- Acronyms SODHI
- 26 Sep 2023 Status has been changed to completed.
- 16 Dec 2019 Planned number of patients changed from 48 to 40.
- 16 Dec 2019 Planned End Date changed from 1 Apr 2021 to 1 Jun 2022.